Appreciate this educated read and contribution, Thankyou.In...

First 72 Last

Share
Profile

Follow
nathan1984

89 Posts.

78

26/07/24

21:47

Post #: 74939510
Share

Originally posted by ajostu: ↑

Well I think the hypothesis that CB has his eyes on more acquisitions is not unfounded.

But let's assume not. Let's assume it's just to accelerate the current program. Again: R&D is currently running (annualised) at about 200m, if Zircaix comes on line as expected then you can easily imagine the company could afford 400m in two years time. So they've effectively raised three years of R&D up front. How are they going to spend it?

One of the questions I ask myself is which critical path issues can be solved by throwing money at them and which are more difficult. Let's pick a trial, say IPAX-II. This is recruiting at 5 locations. Given more money, would it have been feasible to open at more locations, or there are limitations (getting personnel with the right expertise, availability of trial subjects) that mean that this trial is going as quickly as reasonably achievable? Are there diminishing returns?

As an aside, I'd love to know how Prostact Global is recruiting so far, because they're looking to hit a milestone next year and US recruitment hasn't opened yet.

Looking at the trial list there are a number of areas (eg bladder cancer) where the Phase I has been finished so it would make sense to get Phase II/III going as hard as possible. I'd always worked on the basis that some of these therapy trials wouldn't clear Ph II/III for at least another 4-5 years; it made sense that this would be the next stage after the three imaging products and 591. Maybe they've decided that's too slow.

I would speculate that another area that would benefit from hitting the afterburners would be... STARBURST. This is the trial where they're trying TLX250 for imaging a wide range of cancers. But... therapy follow imaging... so maybe if that could be expanded/ accelerated it would have the double whammy of opening up the imaging market even more and opening up opportunities for therapy. I still think that this is the trial that could, long term, be the most transformative for the company, and in my amateur opinion is the one I'd like to see results for the soonest.

Expand

Appreciate this educated read and contribution, Thankyou.

In adding to your view about transformative agents for the company, I do believe that the 153sm for pain management of bone metastases could be huge if successful and commercial.

153Sm-DOTMP is a novel investigational kit-based bone-seeking targeted radiopharmaceutical that uses a “next-generation” chelating agent to deliver a proprietary formulation of Samarium-153 radioisotope. With two major potential applications – pain management of bone metastases and osteosarcoma therapy, including in paediatric patients

TLX Price at posting: $19.32 Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

DUR

Duratec snags $76.5M in works from Woodside and Defence respectively - including spy network upgrade

SDF

Steadfast Group sees $600M wiped off on resumed trades after Four Corners feature

FRB

Firebird snaffles Environmental Permit for Jinshi plant

FBR

FBR's robotic home construction tech passes first US early-stage structural compliance check

GL1

Global Lithium latest hit by lithium downturn; shares fall -10% as Manna DFS paused

There are more pages in this discussion • 10 more messages in this thread...

First 72 Last

Add TLX (ASX) to my watchlist

(20min delay)
Last $18.02		Change 0.465(2.65%)		Mkt cap ! $6.020B

Open	High	Low	Value	Volume
$17.80	$18.06	$17.63	$9.641M	540.5K

Buyers (Bids)

No.	Vol.	Price($)
8	1167	$18.01

Sellers (Offers)

Price($)	Vol.	No.
$18.02	35	3

View Market Depth

No.	Vol.	Price($)
18	1646	18.020
13	2862	18.010
16	1956	18.000
14	1996	17.990
8	1070	17.980

Price($)	Vol.	No.
18.030	749	9
18.040	702	5
18.050	2310	8
18.060	2173	10
18.070	2451	9

Last trade - 15.22pm 10/09/2024 (20 minute delay)

TLX (ASX) Chart

Appreciate this educated read and contribution, Thankyou.In...

Duratec snags $76.5M in works from Woodside and Defence respectively - including spy network upgrade

Steadfast Group sees $600M wiped off on resumed trades after Four Corners feature

Firebird snaffles Environmental Permit for Jinshi plant

FBR's robotic home construction tech passes first US early-stage structural compliance check

Global Lithium latest hit by lithium downturn; shares fall -10% as Manna DFS paused

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Appreciate this educated read and contribution, Thankyou.In...

Top Stories

Duratec snags $76.5M in works from Woodside and Defence respectively - including spy network upgrade

Steadfast Group sees $600M wiped off on resumed trades after Four Corners feature

Firebird snaffles Environmental Permit for Jinshi plant

FBR's robotic home construction tech passes first US early-stage structural compliance check

Global Lithium latest hit by lithium downturn; shares fall -10% as Manna DFS paused

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News